Blog

Hung Trinh: Johnson and Johnson’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study

Hung Trinh/LinkedIn

Jul 7, 2025, 04:07

Hung Trinh: Johnson and Johnson’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study

Hung Trinh, Senior Director of Business Development at OBiO Tech and Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:

“J&J’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study

Analysts at Truist Securities called J&J’s CAR T readout “compelling,” noting that the efficacy figures could position the cell therapy as a formidable competitor to the current standard of care, Gilead’s Yescarta.

Johnson and Johnson’s investigational CAR T therapy JNJ-4496 elicited a treatment response in up to 100% of dosed patients with large B cell lymphoma, posing a challenge to Gilead’s current standard of care Yescarta.

Data from the Phase Ib trial, presented at the 2025 congress of the European Hematology Association on Friday, showed a 100% objective response rate (ORR) in patients with relapsed or refractory disease who had undergone one prior line of therapy. Complete response (CR) in this subgroup was 80%. In patients who had received two or more treatments, JNJ-4496’s ORR and CR rates dipped slightly to 92% and 75%, respectively.

In an investor note on Saturday, Truist Securities called these data “compelling,” noting that they represent an “encouraging step up from the current standard of care, Yescarta.” For instance, in the second-line setting, Yescarta, a CAR T manufactured by Kite, showed a 65% CR, dropping to 36% in the third-line, according to the analysts.

“High CR rates in a cross-trial [comparison] vs Yescarta were observed regardless of prior lines of therapy,” Truist added, however noting that JNJ-4496’s true edge was in safety.

The Phase Ib study documented no cases of grade 3 or 4 cytokine release syndrome, a common adverse effect in immunotherapies. However, 84% of patients developed grade 3 or 4 treatment-emergent serious adverse events, the most of which was neutropenia, or low levels of a type of white blood cell.”

Read Full Article.

More posts featuring Hung Trinh on OncoDaily.